Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Azstarys
Generic Name
Serdexmethylphenidate And Dexmethylphenidate
Active Ingredient
DexmethylphenidateCategory
Other
Salt Form
Hydrochloride
Variants
3
References used for this content
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Azstarys, you must consult a qualified healthcare professional.
Detailed information about Azstarys
Dexmethylphenidate is a central nervous system stimulant primarily used to treat Attention Deficit Hyperactivity Disorder (ADHD). It is the more active d-threo-enantiomer of methylphenidate.
For adults diagnosed with ADHD, the dosage of dexmethylphenidate must be individualized based on therapeutic needs and patient response.
Dexmethylphenidate is FDA-approved for use in children aged 6 years and older. It is not recommended for children under the age of 6, as safety and efficacy have not been established in this age group.
There are no specific dosage adjustment guidelines provided by the manufacturer for patients with renal impairment. Since dexmethylphenidate is primarily metabolized into an inactive metabolite and excreted by the kidneys, significant accumulation of the active drug is unlikely. However, caution is advised in patients with severe renal disease.
Specific guidelines for hepatic impairment are not available. However, because the primary metabolic pathway involves de-esterification (not CYP450 metabolism), hepatic dysfunction may not significantly alter the clearance of the drug. Nevertheless, patients with liver disease should be monitored closely.
Clinical studies of dexmethylphenidate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range.
If a dose is missed, it should be taken as soon as remembered, unless it is late in the afternoon or evening. If it is near the time for the next day's dose, skip the missed dose and resume the regular schedule. Do not 'double up' or take two doses at once to make up for a missed one, as this increases the risk of side effects.
Signs of a dexmethylphenidate overdose may include vomiting, agitation, tremors, muscle twitching, seizures, confusion, hallucinations, sweating, flushing, headache, high fever, fast or irregular heartbeat, high blood pressure, and dilated pupils. In the event of a suspected overdose, contact a poison control center or seek emergency medical attention immediately.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop the medication without medical guidance, as sudden discontinuation can lead to withdrawal symptoms.
Common side effects are those that occur in more than 10% of patients. These are often dose-dependent and may diminish over time as the body adjusts to the medication.
Dexmethylphenidate is a powerful CNS stimulant that requires careful medical supervision. Before starting treatment, patients must undergo a comprehensive medical history review, specifically focusing on cardiovascular health and psychiatric history. It is essential to understand that this medication is a Schedule II controlled substance, meaning it has a high potential for misuse and must be stored securely to prevent theft or unauthorized use.
Abuse, Misuse, and Addiction: Dexmethylphenidate has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants can result in overdose and death. Before prescribing, healthcare providers must assess each patient's risk for abuse. Throughout treatment, patients should be monitored for signs of misuse, such as taking more than the prescribed dose or using the drug for non-medical reasons.
Risks of Sudden Death: Misuse of CNS stimulants may cause sudden death and serious cardiovascular adverse events.
There are several conditions where the risks of using dexmethylphenidate clearly outweigh any potential benefits. In these cases, the medication must not be used.
Dexmethylphenidate is classified as Pregnancy Category C under the older FDA system. There are no adequate and well-controlled studies in pregnant women. Animal studies have shown some evidence of teratogenicity (birth defects) and fetal toxicity at very high doses.
Dexmethylphenidate hydrochloride is a central nervous system (CNS) stimulant. It is the d-threo-enantiomer of racemic methylphenidate. It acts primarily as a norepinephrine-dopamine reuptake inhibitor (NDRI). It achieves its effect by binding to the dopamine transporter (DAT) and the norepinephrine transporter (NET) on the presynaptic membrane of neurons. This binding prevents the reabsorption of these neurotransmitters from the synaptic cleft back into the neuron. Consequently, there is an increase in the extracellular levels of dopamine and norepinephrine, which enhances dopaminergic and noradrenergic neurotransmission in the brain, particularly in the prefrontal cortex and striatum.
The pharmacodynamic effects of dexmethylphenidate include increased alertness, improved attention span, and decreased impulsivity. It also has peripheral effects, such as increasing heart rate and blood pressure, and acting as a mild bronchodilator. Tolerance to the behavioral effects can develop over months or years of use, though the mechanism for this tolerance is complex and may involve down-regulation of receptors.
| Parameter | Value |
Common questions about Azstarys
Dexmethylphenidate is primarily used to treat Attention Deficit Hyperactivity Disorder (ADHD) in children, adolescents, and adults. It works by increasing the levels of certain chemicals in the brain, specifically dopamine and norepinephrine, which help improve focus and reduce impulsivity. By enhancing these neurotransmitter signals, it helps patients manage symptoms like distractibility and hyperactivity. It is often used as part of a comprehensive treatment plan that includes behavioral therapy. Only a qualified healthcare provider can diagnose ADHD and determine if this medication is appropriate.
The most frequently reported side effects include decreased appetite, abdominal pain, nausea, and insomnia. Many patients also experience dry mouth or a slight increase in heart rate and blood pressure. These effects are often most noticeable when first starting the medication or after a dose increase. In most cases, these side effects are mild and may improve as the body adjusts to the drug. However, if they become persistent or bothersome, you should consult your doctor for a possible dose adjustment.
No, you should avoid drinking alcohol while taking dexmethylphenidate. Alcohol can interact with the medication to increase the risk of cardiovascular side effects, such as a rapid heartbeat or high blood pressure. For those taking the extended-release (XR) version, alcohol can cause the medication to be released too quickly into the bloodstream, which is known as 'dose dumping.' This can lead to dangerously high levels of the drug in your system and increase the risk of an overdose. Always talk to your doctor about the risks of alcohol consumption with your specific medications.
The safety of dexmethylphenidate during pregnancy has not been fully established through clinical trials. It is classified as a drug that should only be used if the potential benefits to the mother outweigh the potential risks to the developing fetus. Some animal studies have suggested possible risks, but human data is limited. If you are pregnant or planning to become pregnant, it is crucial to discuss the risks and benefits with your healthcare provider. They may suggest joining a pregnancy registry to help monitor the health of both mother and baby.
The immediate-release (IR) version of dexmethylphenidate typically begins to work within 30 to 60 minutes after ingestion. The extended-release (XR) version also provides an initial release that starts working quickly, usually within the first hour. While the physical effects on focus and attention are often felt with the first few doses, it may take several weeks of titration to find the optimal dose for long-term symptom management. Your doctor will monitor your progress closely during the initial weeks of treatment. Consistency in taking the medication as prescribed is key to its effectiveness.
Stopping dexmethylphenidate abruptly after long-term use is generally not recommended. Doing so can lead to a 'rebound' of ADHD symptoms or withdrawal symptoms such as extreme tiredness, depression, and sleep disturbances. If you need to stop the medication, your doctor will usually provide a schedule to gradually taper your dose. This helps your brain adjust slowly and minimizes the risk of negative emotional or physical effects. Always consult your healthcare provider before making any changes to how you take your medication.
If you miss a dose, take it as soon as you remember, but avoid taking it late in the afternoon or evening as it may cause insomnia. If it is already late in the day, it is usually better to skip the missed dose and wait until the next morning to take your regular dose. Never take a double dose to make up for the one you missed, as this increases the risk of side effects like high blood pressure or anxiety. If you frequently forget your doses, consider using a pill organizer or setting a daily alarm. Consult your pharmacist if you are unsure about the timing.
No, dexmethylphenidate is much more likely to cause weight loss rather than weight gain. As a stimulant, it commonly suppresses appetite, which can lead to reduced caloric intake, especially during the hours the medication is active. In children, healthcare providers monitor height and weight closely to ensure that growth is not being negatively impacted. If significant weight loss occurs, your doctor may suggest strategies such as eating high-calorie meals before taking the medication or after it wears off. In some cases, a 'drug holiday' during school breaks may be recommended.
Dexmethylphenidate can interact with several other types of medications, so it is vital to inform your doctor of everything you are taking. It should never be taken with MAOIs, and caution is needed when combining it with blood pressure medications, blood thinners, or certain antidepressants. Some over-the-counter cold medicines containing decongestants can also increase heart rate and blood pressure when combined with stimulants. Your pharmacist can perform a comprehensive drug interaction check to ensure your regimen is safe. Always seek medical advice before starting any new supplement or medication while on dexmethylphenidate.
Yes, dexmethylphenidate is available in generic form for both the immediate-release (IR) and extended-release (XR) formulations. Generic medications are required by the FDA to have the same active ingredient, strength, dosage form, and route of administration as the brand-name drug. Using the generic version can often significantly reduce the out-of-pocket cost for patients and insurance providers. While the inactive ingredients (like fillers or dyes) may differ slightly, the therapeutic effect should be the same. Talk to your pharmacist to see if a generic version is a suitable and cost-effective option for you.
Other drugs with the same active ingredient (Dexmethylphenidate)
> Warning: Stop taking Dexmethylphenidate and call your doctor immediately if you experience any of the following serious symptoms.
Dexmethylphenidate carries an FDA Black Box Warning regarding its potential for Abuse and Dependence.
Summary of Warning: CNS stimulants, including dexmethylphenidate, have a high potential for abuse and dependence. Healthcare providers should assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy. Maintaining careful prescription records and educating patients and families on the proper storage and disposal of the medication is essential to prevent diversion (sharing or selling the drug).
Report any unusual symptoms or persistent side effects to your healthcare provider immediately. They may adjust your dose or suggest a different treatment plan.
Patients on long-term dexmethylphenidate therapy require regular follow-up appointments. Monitoring typically includes:
Dexmethylphenidate may cause dizziness, blurred vision, or other CNS effects that can impair physical or mental abilities. Patients should be cautious when driving a car or operating heavy machinery until they are certain the medication does not adversely affect their performance.
Alcohol should be avoided while taking dexmethylphenidate. Alcohol can exacerbate the side effects of stimulants, such as increased heart rate and blood pressure. Furthermore, in the case of extended-release (XR) formulations, alcohol can cause 'dose dumping,' where the entire day's dose is released into the bloodstream at once, significantly increasing the risk of toxicity.
Do not stop taking dexmethylphenidate abruptly without consulting your doctor. Sudden discontinuation after prolonged use can lead to a 'crash' or withdrawal syndrome, characterized by extreme fatigue, depression, and changes in sleep patterns. A gradual tapering of the dose is usually recommended to minimize these effects.
> Important: Discuss all your medical conditions, especially any history of heart problems or mental health issues, with your healthcare provider before starting Dexmethylphenidate.
Dexmethylphenidate is not known to significantly interfere with most common laboratory tests. However, it may cause a false-positive result for amphetamines on some rapid urine drug screens. If a drug test is required (e.g., for employment), it is important to disclose the prescription for dexmethylphenidate to the testing facility.
For each major interaction, the primary management strategy is close clinical monitoring of the patient's vital signs and therapeutic response. Dose adjustments of either the stimulant or the interacting medication may be necessary.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking to prevent dangerous drug interactions.
These are conditions that require a careful risk-benefit analysis and intense monitoring if the drug is prescribed.
Patients who have had a negative reaction to racemic methylphenidate (Ritalin, Concerta) are highly likely to have a similar reaction to dexmethylphenidate. While dexmethylphenidate is only one half of the racemic mixture, the pharmacological profile is nearly identical in terms of allergenicity and side effect profile.
> Important: Your healthcare provider will evaluate your complete medical history, including any family history of sudden death or mental illness, before prescribing Dexmethylphenidate.
Dexmethylphenidate is approved for children 6 years and older.
There is very little data regarding the use of dexmethylphenidate in patients over 65.
In patients with kidney disease, the primary concern is the accumulation of metabolites. While ritalinic acid is inactive, its clearance is delayed in renal failure. However, no specific dose adjustments are currently mandated for dexmethylphenidate in renal impairment. Dialysis is not an effective treatment for overdose because the drug has a large volume of distribution.
Since the liver is not the primary site of active drug metabolism (de-esterification occurs in various tissues), mild to moderate hepatic impairment may not significantly alter the drug's levels. However, patients with severe liver cirrhosis should be treated with extreme caution.
> Important: Special populations require individualized medical assessment and frequent monitoring to ensure safety and efficacy.
| Bioavailability | ~22-25% (Extensive first-pass metabolism) |
| Protein Binding | 12% to 15% |
| Half-life | 2 to 3 hours |
| Tmax (IR) | 1 to 1.5 hours |
| Tmax (XR) | 1.5 hours and 6.5 hours (Bimodal) |
| Metabolism | De-esterification via CES1A1 to d-ritalinic acid |
| Excretion | Renal 90%, Fecal 1-3% |
Dexmethylphenidate is classified as a CNS stimulant of the phenethylamine and piperidine classes. It is pharmacologically related to other stimulants like amphetamines, although its mechanism (reuptake inhibition) differs slightly from amphetamines (which also promote neurotransmitter release).